Baker Bros. Advisors’s VYNE Therapeutics VYNE Stock Holding History

Baker Bros. Advisors’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-851,353	Closed	-$285K	–	98
2025 Q3	$285K	Buy	+851,353	New	+$557K	﹤0.01%	87
2020 Q2	–	Sell	-8,685	Closed	-$1.68M	–	120
2020 Q1	$1.68M	Sell	8,685 -1,037	-11%	-$325K	0.01%	94
2019 Q4	$3.25M	Hold	9,722	–	–	0.02%	81
2019 Q3	$3.14M	Hold	9,722	–	–	0.02%	75
2019 Q2	$4.19M	Hold	9,722	–	–	0.03%	66
2019 Q1	$5.5M	Hold	9,722	–	–	0.04%	57
2018 Q4	$2.88M	Hold	9,722	–	–	0.02%	65
2018 Q3	$6.89M	Hold	9,722	–	–	0.05%	62
2018 Q2	$5.68M	Hold	9,722	–	–	0.04%	70
2018 Q1	$26.3M	Buy	+9,722	New	+$23.6M	0.22%	36

Other funds holding VYNE

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

T3 Companies New York $76.8M AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Baker Bros. Advisors's VYNE Position: Q4 2025 in Review

Baker Bros. Advisors sold out of VYNE Therapeutics (VYNE) in Q4 2025, closing a stake of 851,353 shares — an estimated $285K sold.

Baker Bros. Advisors first reported a position in VYNE in Q1 2018 and held it in 10 quarters. The position peaked at $26.3M in Q1 2018. 44 funds tracked by Wall St. Rank hold VYNE as of Q4 2025.

Baker Bros. Advisors reported no remaining VYNE Therapeutics position as of Q4 2025 after selling out during the quarter.
Baker Bros. Advisors sold 851,353 VYNE Therapeutics shares in Q4 2025, an estimated $285K.
Baker Bros. Advisors first reported a position in VYNE Therapeutics in Q1 2018 and held it in 10 quarters.
Baker Bros. Advisors's VYNE Therapeutics position peaked at $26.3M in Q1 2018.
44 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2025.

Based on Baker Bros. Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.